Qu, Fangfei
Brough, Siqi C. http://orcid.org/0000-0001-9779-4174
Michno, Wojciech http://orcid.org/0000-0002-3096-3604
Madubata, Chioma J.
Hartmann, Griffin G. http://orcid.org/0000-0001-9213-8995
Puno, Alyssa
Drainas, Alexandros P. http://orcid.org/0000-0001-9081-9850
Bhattacharya, Debadrita
Tomasich, Erwin http://orcid.org/0000-0002-7069-2247
Lee, Myung Chang http://orcid.org/0000-0002-7051-5822
Yang, Dian
Kim, Jun
Peiris-Pagès, Maria
Simpson, Kathryn L. http://orcid.org/0000-0002-4386-0401
Dive, Caroline
Preusser, Matthias
Toland, Angus
Kong, Christina http://orcid.org/0000-0003-2098-6842
Das, Millie
Winslow, Monte M. http://orcid.org/0000-0002-5730-9573
Pasca, Anca M. http://orcid.org/0000-0002-0445-9009
Sage, Julien http://orcid.org/0000-0002-8928-9968
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA217450)
Damon Runyon Cancer Research Foundation (DRG-2322-18)
Tobacco-Related Disease Research Program (T32DT4747)
Article History
Received: 3 May 2022
Accepted: 25 August 2023
First Online: 2 October 2023
Competing interests
: J.S. licensed a patent to Forty Seven/Gilead on the use of CD47-blocking strategies in SCLC and has equity in, and is an advisor for, DISCO Pharmaceuticals. M.M.W. has equity in, and is an advisor for, D2G Oncology. M.D. has received recent research support from Novartis, Abbvie, United Therapeutics, Verily and Varian, and has consulted with Beigene, Astra Zeneca and Jazz Pharmaceuticals. M.P. has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals and Servier. The other authors declare no competing interests.